| |||||||
Novartis
enters into research collaboration with Morphochem for use of its
MOREsystem™ in lead discovery
Munich
, Dr Peter Seufer-Wasserthal, VP Business Development at Morphochem, commented: “This collaboration nicely fits our vision of working with partners to apply our integrated discovery technologies in parallel on a number of targets to identify compounds active against these targets. These compounds will then be further refined applying genetic algorithms in an evolutionary way in which multi parametric optimisation is used to identify compounds suited as potential drug candidates.” -ends- Morphochem
AG discovers
and develops highly selective small molecule compounds for the medicines of
tomorrow. The company integrates novel chemistries with biological screening on
the basis of its proprietary MolMind™ technology. Its unique and highly
integrated chemical genomics platform provides a continuous flow of novel drug
candidates for unmet medical needs in major areas of indications such as cancer
and anti-infectives Morphochem
was founded in For
further information, please contact: Morphochem:
Thomas Loeser, CFO, tel: +49 (0)89 78 00 50, email: thomas.loeser@morphochem.de Dr
Peter Seufer-Wasserthal, VP Business Development, tel: +43 (0)7673 321511,
email: peter.seufer@morphochem.de Media enquiries: Sue Charles, CEO Northbank Communications, tel: +44 (0)20 7886 8152, email: s.charles@northbankcommunications.com |
|
| ||||||||